ArticleJCO clinical cancer informatics2026
Multicentric Validation of a Complete Blood Count-Based Model for Breast Cancer Risk Stratification in Women Age 40-49 Years.
Article in JCO clinical cancer informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecent changes in breast cancer (BC) screening guidelines have extended eligibility to women age 40-49 years, yet risk stratification in this group remains challenging. This study evaluated the performance of a complete blood count (CBC)-based BC risk model, originally developed for women age 40-70 years, in women age 40-49 years across diverse clinical settings in Brazil.
methodsIn this retrospective multicenter study, CBC data from 239,089 women age 40-49 years were analyzed. A ridge regression model using age, neutrophil-to-lymphocyte ratio (NLR), and RBC was evaluated. CBCs were stratified by timing relative to breast diagnostic procedures: same day, 1-90 days prior, and 91-180 days prior. Model performance was assessed using area under the receiver operating characteristic curve (AUC), sensitivity, and specificity, with leave-one-group-out cross-validation across five Brazilian clinical settings.
resultsThe CBC model showed stable performance when CBCs were obtained within 3 months before diagnosis (AUC = 0.63 ± 0.03 for same day; 0.61 ± 0.05 for 1-90 days prior). Performance declined in the 91- to 180-day interval (AUC = 0.58 ± 0.03). NLR increased significantly closer to diagnosis, driven mainly by neutrophilia. At 70% specificity, screening the top 30% identified 47% of cancers (relative risk = 2.07).
conclusionThe CBC-based model provides a low-cost approach to BC risk stratification in women age 40-49 years, particularly when CBCs are collected within 3 months of evaluation. This opportunistic strategy may be especially valuable in resource-constrained settings where routine mammographic screening is limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.